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Background: Transthyretin-mediated amyloidosis is an inherited, progressively debilitating disease caused by mutations
in the transthyretin gene. This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of
multiple doses of patisiran (ALN-TTR02), a small interfering RNA encapsulated within lipid nanoparticles, in patients with
transthyretin-mediated familial amyloid polyneuropathy (FAP).
Methods: In this phase II study, patients with FAP were administered 2 intravenous infusions of patisiran at one of the
following doses: 0.01 (n = 4), 0.05 (n = 3), 0.15 (n = 3), or 0.3 (n = 7) mg/kg every 4 weeks (Q4W), or 0.3 mg/kg (n = 12)
every 3 weeks (Q3W).
Results: Of 29 patients in the intent-to-treat population, 26 completed the study. Administration of patisiran led
to rapid, dose-dependent, and durable knockdown of transthyretin, with the maximum effect seen with patisiran
0.3 mg/kg; levels of mutant and wild-type transthyretin were reduced to a similar extent in Val30Met patients. A
mean level of knockdown exceeding 85 % after the second dose, with maximum knockdown of 96 %, was observed
for the Q3W dose. The most common treatment-related adverse event (AE) was mild-to-moderate infusion-related
reactions in 10.3 % of patients. Four serious AEs (SAEs) were reported in 1 patient administered 0.3 mg/kg Q3W (urinary
tract infection, sepsis, nausea, vomiting), and 1 patient administered 0.3 mg/kg Q4W had 1 SAE (extravasation-related
cellulitis).
Conclusions: Patisiran was generally well tolerated and resulted in significant dose-dependent knockdown of
transthyretin protein in patients with FAP. Patisiran 0.3 mg/kg Q3W is currently in phase III development.
Trial registration number: NCT01617967.
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Transthyretin (TTR) is a tetrameric protein produced
primarily in the liver. Mutations in the TTR gene
destabilize the tetramer, leading to misfolding of mono-
mers and aggregation into TTR amyloid fibrils (ATTR).
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spectrum of disease symptoms. The most common mu-
tations associated with familial amyloid polyneuropathy
(FAP) and ATTR-associated cardiomyopathy, respect-
ively, are Val30Met [4] and Val122Ile [5].
Treatment options for FAP focus on stabilizing or de-
creasing the amount of circulating amyloidogenic protein.
Orthotopic liver transplantation reduces mutant TTR
levels [6], with improved survival reported in patients with
early-stage FAP, although deposition of wild-type TTR
may continue [7–12]. Tafamidis and diflunisal stabilizeis distributed under the terms of the Creative Commons Attribution 4.0
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ease progression [4, 13–15]. However, symptoms continue
to worsen on treatment in many patients [4, 13–15],
highlighting the need for new, disease-modifying treat-
ment options for FAP.
RNA interference is a cellular process that controls gene
expression, in which small interfering RNAs (siRNAs) me-
diate the cleavage of specific messenger RNAs (mRNAs)
[16, 17]. Lipid nanoparticles (LNPs) deliver siRNAs to he-
patocytes, resulting in the robust and durable reduction in
expression (so-called “knockdown”) of gene targets across
multiple species [18–23]. Patisiran (ALN-TTR02) com-
prises a TTR mRNA-specific siRNA formulated in LNPs
[20]. A phase I ascending-dose study in healthy volunteers
demonstrated rapid, dose-dependent, and durable knock-
down of serum TTR with patisiran [20]. The objective of
this study was to evaluate the safety, tolerability, pharma-
cokinetics (PK), and pharmacodynamics (PD) of multiple
ascending intravenous (IV) doses of patisiran in patients
with FAP.
Methods
Patients
Eligible patients were adults (≥18 years) with biopsy-
proven ATTR amyloidosis and mild-to-moderate neur-
opathy; Karnofsky performance status ≥ 60 %; body mass
index 17–33 kg/m2; adequate liver and renal function
(aspartate transaminase [AST] and alanine transaminase
[ALT] ≤ 2.5 × the upper limit of normal [ULN], total bili-
rubin within normal limits, albumin > 3 g/dL, inter-
national normalized ratio ≤ 1.2, serum creatinine ≤ 1.5
ULN); and seronegativity for hepatitis B virus and hepa-
titis C virus. Patients were excluded if they had a liver
transplant; had surgery planned during the study; were
HIV-positive; had received an investigational drug other
than tafamidis or diflunisal within 30 days; had a New
York Heart Association heart failure classification > 2;
were pregnant or nursing; had known or suspected
systemic bacterial, viral, parasitic, or fungal infections;
had unstable angina; had uncontrolled clinically signifi-
cant cardiac arrhythmia; or had a prior severe reaction
to a liposomal product or known hypersensitivity to
oligonucleotides.
Study design
This was a multicenter, international, open-label, multiple-
dose escalation phase II study of patisiran in patients
with FAP. Cohorts of 3 patients received 2 doses of
patisiran, with each dose administered as an IV infu-
sion. Cohorts 1–3 received 2 doses of patisiran 0.01,
0.05, and 0.15 mg/kg every 4 weeks (Q4W), respect-
ively; cohorts 4 and 5 both received 2 doses of patisiran
0.3 mg/kg Q4W. All patients in cohorts 6–9 received 2
doses of patisiran 0.3 mg/kg administered every 3 weeks(Q3W). As lipid-based delivery systems have previously
been associated with adverse immune events [24, 25],
all patients received premedication prior to each pati-
siran infusion consisting of dexamethasone, paraceta-
mol (acetaminophen), an H2 blocker (e.g. ranitidine or
famotidine), and an H1 blocker (e.g. cetirizine, hy-
droxyzine, or fexofenadine) to reduce the risk of
infusion-related reactions (further details on pre-
medication regimen are provided in Additional file 1).
Patisiran was administered IV at 3.3 mL/min over
60 min, or over 70 min using a micro-dosing regimen
(1.1 mL/min for 15 min followed by 3.3 mL/min for
the remainder of the dose). Cumulative safety and tol-
erability data on all patients was reviewed by the Safety
Review Committee (SRC). This study provides Class III
evidence on the efficacy and safety of patisiran in
patients with FAP.
Standard protocol approvals, registrations, and patient
consents
The study procedures (Clinicaltrials.gov identifier:
NCT01617967) were approved by the ethics committee
on human experimentation at each site. All patients
provided written informed consent.
Outcome measures
The primary study objective was to evaluate the safety
and tolerability of multiple ascending doses of patisiran.
Secondary objectives were to characterize the plasma
and urine PK of patisiran, and to assess preliminary evi-
dence of the PD effect of patisiran on serum total TTR
protein levels.
Serum levels of total TTR protein were assessed for all
patients using an enzyme-linked immunosorbent assay
(ELISA). Additionally, wild-type and mutant TTR pro-
tein were separately and specifically measured in serum
for patients with the Val30Met mutation using a propri-
etary mass spectrometry method (Charles River Labora-
tories, Quebec, Canada). Serum samples were collected
at screening, and on Days 0, 1, 2, 7, 10, 14, 21, 22, 23
(Q3W only); 28, 29 (Q4W only); 30 (Q4W only); 31
(Q3W only); 35, 38 (Q4W only); and 42, 49, 56, 112,
and 208 of follow-up.
Plasma concentration–time profiles were created for
TTR siRNA, based on blood samples collected on Day 0
and at the following time points: pre-dose (within 1 h of
planned dosing start), at end of infusion (EOI), at 5, 10,
and 30 min, and at 1, 2, 4, 6, 24, 48, 168, 336, 504 (Day
21, Q3W regimen only), and 672 h (Day 28, Q4W regi-
men only) post-infusion. Additional samples were col-
lected on Days 84 and 180 for the Q4W regimens, and
on Days 35, 91, and 187 for the Q3W regimen. For
cohorts 3–9, blood samples on Day 0 at EOI and 2 h
post-infusion were also analyzed for both free and
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lyzed using a validated ATTO-Probe high-performance
liquid chromatography (HPLC) assay (Tandem Labora-
tories, Salt Lake City, Utah, USA). PK analyses were
conducted using non-compartmental and/or compart-
mental evaluation of TTR siRNA plasma concentration–
time data to determine PK parameter estimates using
the validated software program WinNonlin®. Urine sam-
ples were analyzed for levels of excreted TTR siRNA,
and renal clearance was measured after dosing.
Serum levels of vitamin A and retinol binding protein
(RBP) were measured by HPLC and nephelometry, re-
spectively, at the same time points specified for total
TTR (Biomins Specialized Medical Pathology, Lyon,
France).
Safety evaluations included assessment of adverse
events (AEs), electrocardiograms (ECGs), arterial oxygen
saturation using pulse oximetry, vital signs, clinical
laboratory safety tests, and physical examinations. AEs
were defined as mild (easily tolerated with no disruption
of normal daily activity), moderate (sufficient discomfort
to interfere with daily activity), or severe (those which
incapacitated and prevented usual activity). The num-
bers and percentages of patients with any treatment-
emergent AE (TEAE), with any serious TEAE, with any
TEAE leading to discontinuation of study medication, or
with any TEAE considered a dose-limiting toxicity were
summarized by dose cohort and overall. Dose-limiting
toxicities included any of the following: any life-
threatening toxicity; ALT and AST ≥ 5 × ULN or total
bilirubin > 2.0 mg/dL; an infusion reaction that required
hospitalization; and any other toxicity that in the opin-
ion of the SRC precluded administration of a second
dose.
Statistical analyses
Based on the planned dose escalation scheme, we ex-
pected to enroll 27 patients. Patient populations in-
cluded intent-to-treat (ITT, all patients who were
enrolled and received study treatment) and per-protocol
(PP, ITT patients with no major protocol violations).
Safety measures were assessed in the ITT population.
No substitutions were made to allow for missing data
points.
Means and variances for TTR knockdown from base-
line were calculated for the PP population, with baseline
defined as the average of all pre-dose values. We used
analysis of variance (ANOVA) and analysis of covariance
(ANCOVA) to analyze the PD data (natural log trans-
formed TTR relative to baseline), with Tukey’s post hoc
tests of individual pairwise comparisons (between dose
levels). Nadir TTR levels were defined as the minimum
level per patient during the 28-day period (21-day period
for Q3W group) after each dose administration (first-dose, second-dose periods: Days 1–28, 29–56, and Days
1–21, 22–42 for Q4W and Q3W groups, respectively).
Relationships between TTR and RBP or vitamin A, rela-
tive to baseline, and the relationship between wild-type
and V30M TTR levels, were explored via linear regres-
sion. We formally evaluated the dose proportionality of
the patisiran component in PK parameters using a
power model analysis. AEs were coded using the Med-
ical Dictionary for Regulatory Activities coding system,
version 15.0, and descriptive statistics provided for AEs,
laboratory data, vital signs data, and ECG interval data.
All statistical analyses were performed using SAS (ver-
sion 9.3 or higher) and/or R (version 2.6 or higher).
Results
Baseline demographics and disease characteristics
A total of 29 patients were enrolled across 7 countries:
Brazil, France, Germany, Portugal, Spain, Sweden, and
the USA. All patients were white, 69 % were male, and
the mean (standard deviation [SD]) age was 56 (15.6)
years (Table 1). The majority of patients (76 %) had the
Val30Met TTR mutation. A small proportion (14 %) of
patients had walking difficulties requiring the use of a
stick or crutch, with the remainder having unimpaired
ambulation. The majority of patients were taking a con-
current TTR tetramer stabilizer, including 48 % on tafa-
midis and 24 % using diflunisal.
Patient disposition
Of the 29 patients enrolled, all received study treatment
and were included in the ITT population, and 26 pa-
tients completed the study. Two patients discontinued
from the study after receiving only 1 dose of patisiran: 1
patient in the 0.01 mg/kg dosing group (cohort 1) dis-
continued following a protocol amendment (Additional
file 1), and 1 patient in the 0.3 mg/kg Q3W group with-
drew from the study because of an AE. Following the
protocol-related patient discontinuation in the 0.01 mg/kg
Q4W group, an additional patient was enrolled and in-
cluded in this dose cohort. In addition to the 2 patients
who discontinued after the first dose of patisiran, 1 patient
in the 0.3 mg/kg Q4W group did not complete the study
due to a protocol violation (missed follow-up assessment).
This patient was excluded from PD analyses after Day 28
owing to an AE (extravasation of the second dose of pati-
siran), and an additional patient was recruited to the
study.
Seven patients received patisiran 0.3 mg/kg Q4W
(cohorts 4 and 5) and 4 patients received patisiran
0.01 mg/kg; all other study cohorts included 3 patients
as described. Of the cohorts treated with patisiran
0.3 mg/kg, 10 patients received their infusions over
60 min, and 9 patients (all in the Q3W group) received
the 70-min micro-dosing regimen. One patient in the
Table 1 Baseline demographics and disease characteristics (intent-to-treat population)
Parameter 0.01 mg/kg 0.05 mg/kg 0.15 mg/kg 0.3 mg/kg 0.3 mg/kg All patients
Q4W Q4W Q4W Q4W Q3W (n = 29)
(n = 4) (n = 3) (n = 3) (n = 7) (n = 12)
Sex, n (%)
Male 3 (75.0) 3 (100.0) 2 (66.7) 3 (42.9) 9 (75.0) 20 (69.0)
Female 1 (25.0) 0 1 (33.3) 4 (57.1) 3 (25.0) 9 (31.0)
Age, years
Mean (SD) 65.8 (8.96) 55.7 (24.83) 41.7 (2.52) 58.7 (16.07) 53.8 (15.6) 55.6 (15.61)
Race, n (%)
White/Caucasian 4 (100.0) 3 (100.0) 3 (100.0) 7 (100.0) 12 (100.0) 29 (100.0)
Country
Portugal 0 1 (33.3) 3 (100.0) 2 (28.6) 3 (25.0) 9 (31.0)
Sweden 2 (50.0) 1 (33.3) 0 2 (28.6) 1 (8.33) 6 (20.7)
France 2 (50.0) 1 (33.3) 0 2 (28.6) 3 (25.0) 8 (27.6)
Brazil 0 0 0 0 1 (8.33) 1 (3.4)
Germany 0 0 0 0 1 (8.33) 1 (3.4)
Spain 0 0 0 0 3 (25.0) 3 (10.3)
United States 0 0 0 1 (14.3) 0 1 (3.4)
TTR genotype, n (%)
Val30Met 2 (50.0) 2 (66.7) 3 (100.0) 6 (85.7) 9 (75.0) 22 (75.9)
Othera 2 (50.0) 1 (33.3) 0 1 (14.3) 3 (25.0) 7 (24.1)
Mean (SD) serum TTR at baseline, μg/mL 272.9 (98.96) 226.5 (12.67) 276.1 (7.65) 242.6 (38.30) 235.5 (44.45) 245.64 (49.44)
FAP stageb
1 – – – – – 25 (86.2)
2 – – – – — 4 (13.8)
Prior exposure to ALN-TTR01c
Yes 2 (50.0) 0 2 (66.7) 3 (42.9) 2 (16.67) 9 (31.0)
No 2 (50.0) 3 (100.0) 1 (33.3) 4 (57.1) 10 (83.33) 20 (69.0)
Concurrent TTR stabilizer use
Diflunisal 2 (50.0) 1 (33.3) 0 3 (42.9) 1 (33.3) 7 (24.1)
Tafamidis 0 1 (33.3) 2 (66.7) 4 (57.1) 7 (66.7) 14 (48.3)
aNon-Val30Met mutations: Arg45Thr (n = 1), Phe46Leu (n = 1), Ser77Tyr (n = 2), Ser77Phe (n = 2), Tyr116Ser (n = 1)
bFAP stage: 1 = unimpaired ambulation, mostly mild neuropathy in lower limbs; 2 = assistance with ambulation required, mostly moderate neuropathy with
progression to lower limbs, upper limbs, and trunk; 3 = wheelchair-bound or bedridden, severe neuropathy of all limbs
cALN-TTR01 was the first-generation siRNA-LNP used in phase I studies in patients with ATTR
ATTR TTR amyloid fibrils, FAP familial amyloid polyneuropathy; Q3W every 3 weeks; Q4W every 4 weeks; SD standard deviation; siRNA-LNP small interfering
RNA-lipid nanoparticles; TTR transthyretin
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criteria because of liver function data, but was given a
waiver to enter the study.
Efficacy and PD
Mean (SD) baseline serum TTR protein levels were simi-
lar across the dose cohorts: 272.9 (98.86), 226.5 (12.67),
276.1 (7.65), 242.6 (38.30), and 235.5 (44.45) μg/mL for
the 0.01, 0.05, 0.15, 0.3 Q4W, and 0.3 mg/kg Q3W dos-
age groups, respectively.In comparison to the 0.01 mg/kg dose cohort, a signifi-
cant reduction in nadir TTR levels (p < 0.001 by post hoc
tests after ANCOVA) was observed after the first and sec-
ond doses of patisiran in the 0.3 mg/kg Q4W and Q3W
cohorts (Fig. 1 and Table 2). In patients given 0.3 mg/kg
Q3W, mean ± SD TTR knockdown from baseline at nadir
was 83.8 ± 5.1 % and 86.7 ± 7.0 % after the first and second
doses, respectively, with maximum knockdown of 96 %. In
patients given the same dose Q4W, mean ± SD TTR
knockdown from baseline at nadir was 82.9 ± 5.4 % and
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Fig. 1 Dose response and duration of TTR knockdown. Mean (±SEM) percentage of baseline serum concentration–time profile. Q3W: every 3 weeks;
Q4W: every 4 weeks; SEM: standard error of the mean; TTR: transthyretin. *Includes first dose data from additional patient prior to protocol
amendment. †Excludes post-Day 28 data from patient who experienced drug extravasation during second infusion. ‡One patient discontinued
before the second dose of patisiran
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with maximum knockdown of 90.8 %. Mean TTR knock-
down from baseline of ≥ 80 % was maintained between
doses in the Q3W cohort, yet TTR levels recovered to <
80 % between doses with the Q4W regimen. In
patients with the Val30Met mutation, a very similar
degree of knockdown was observed for wild-type and
mutant TTR (Fig. 2a and b). The levels of mutant and
wild-type TTR knockdown were not assessed for each
of the rarer non-Val30Met genotypes, although overall
knockdown, as measured by ELISA, was indistinguishable
between patients with Val30Met or non-Val30Met muta-
tions. The level of serum TTR knockdown was highly
correlated with the reduction in circulating level of RBP
(r2 = 0.89, p < 10−15) and vitamin A (r2 = 0.89, p < 10-15)
(Additional file 2: Figure S1).Table 2 Serum TTR knockdown by dose group
Dose group (mg/kg) Dose 1
Maximum TTR KD (%) TTR KD at Nadir (Mean
0.01 Q4W (n = 4a) 37.8 22.1 ± 12.5
0.05 Q4W (n = 3) 58.0 48.4 ± 16.2
0.15 Q4W (n = 3) 81.7 74.5 ± 6.8***
0.3 Q4W (n = 7b) 87.5 82.9 ± 5.4***
0.3 Q3W (n = 12c) 94.2 83.8 ± 5.1***
p values from ANCOVA models including baseline TTR as covariate and dose group
***p < 0.001 vs. 0.01 mg/kg group
aIncludes first-dose data from additional patient prior to protocol amendment
bExcludes post-day 28 data from patient who experienced drug extravasation durin
cOne patient discontinued the study before second dose of patisiran
ANCOVA analysis of variance; KD knockdown; Q3W every 3 weeks; Q4W every 4 weeAlthough patients taking tafamidis or diflunisal had
significantly increased baseline levels of serum TTR
compared with patients not taking stabilizer therapy
(p < 0.001 by ANOVA) (Additional file 3: Figure S2a),
patisiran administration resulted in a similar degree of
TTR knockdown in these 2 patient groups (Additional
file 3: Figure S2b).
PK
Mean concentrations of the patisiran TTR siRNA compo-
nent decreased after EOI (Additional file 4: Figure S3),
and there was no accumulation of siRNA following the
second dose on Day 21/28. Measurements of encapsulated
versus un-encapsulated concentrations of TTR siRNA
after each dose indicated stability of the circulating LNP
formulation. For both the first and second doses, theDose 2
% ± SD) Maximum TTR KD (%) TTR KD at Nadir (Mean % ± SD)
34.4 32.9 ± 2.3
58.5 46.9 ± 15.0
86.0 77.0 ± 7.8
90.8 85.7 ± 9.6***
96.0 86.7 ± 7.0***
s as factor; models significant at p < 0.001 for Dose 1, p < 0.001 for Dose 2
g second infusion
ks; SD standard deviation; TTR transthyretin
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Fig. 2 Effect of patisiran on wild-type and mutant TTR in patients with the Val30Met mutation. a All post-dose data. b Patisiran 300 mg/kg groups
(error bars represent SEM). Q3W: every 3 weeks; Q4W: every 4 weeks; SEM: standard error of the mean; TTR: transthyretin; wt: wild-type
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and area under the plasma concentration–time curve
from zero to the last measurable time point (AUC0–last)
increased in a dose-proportional manner over the dose
range tested. Cmax and AUC0–last after doses 1 and 2 were
comparable, with no accumulation. The median terminal
half-life of patisiran at Day 0 and Days 21/28 was 39–59 h
at doses > 0.01 mg/kg, and was relatively unchanged when
comparing doses 1 and 2 for each dose cohort.Safety and tolerability
The most common TEAE related to study drug was
mild-to-moderate infusion-related reaction (IRR), which
occurred in 3/29 patients overall (10.3 %), all in the
0.3 mg/kg Q4W group (Table 3); none of these TEAEs
led to discontinuation of treatment. IRR-associated
symptoms were tachycardia, decreased oxygen satur-
ation, dizziness, abdominal pain, bronchospasm, dys-
pnea, erythema, chills, pallor, pyrexia, and tachypnea.
For 1 patient with a mild reaction, the event was man-
aged by prolonging the IV infusion time. Of note, no
IRRs were reported in the patient cohort that received
0.3 mg/kg Q3W (n = 12), 9 of whom received their infu-
sion with the micro-dosing regimen administered over
70 min. Aside from IRRs, no drug-related TEAE was ob-
served in more than 1 patient per dosage group across
the study.There were no dose-limiting toxicities or deaths due
to TEAEs reported during the course of the study. The
majority of TEAEs were of mild or moderate intensity.
Four serious AEs (SAEs) were reported in 1 patient in
the 0.3 mg/kg Q3W group (urinary tract infection, sep-
sis, nausea, and vomiting), and the patient withdrew
from the study because of the nausea and vomiting. An
additional SAE (extravasation-related cellulitis) was re-
corded in 1 patient in the 0.3 mg/kg Q4W group. The
SAEs of nausea and vomiting, and cellulitis were each
recorded by the Investigator as related to the study drug.
No clinically significant changes in liver function tests,
renal function, or hematologic parameters were re-
corded. Transient increases in white blood cell count
were observed approximately 24 h after each patisiran
infusion, which were considered related to dexametha-
sone premedication. There were no substantial changes
in serum G-CSF, IFN-α, IFN-γ, IL-1b, IL-12, and TNF-α
cytokines. Values were below the lower limit of detection
for most patients at the majority of time points. Transi-
ent increases in mean levels of IL-6, IL-1RA, and IP10
were observed after patisiran infusion in the 0.3 mg/kg
Q4W group (and in the 0.3 mg/kg Q3W group for IL-6),
although levels returned to baseline within 24 h. Tran-
sient increases in mean levels of complement factor Bb
were also seen after infusion of patisiran doses 0.05–
0.3 mg/kg. None of these elevations were associated
with AEs.
Table 3 Treatment-emergent adverse events related or possibly related to patisiran (ITT [safety] population)
Preferred term, n (%) Patisiran
0.01 mg/kg 0.05 mg/kg 0.15 mg/kg 0.3 mg/kg 0.3 mg/kg
Q4W Q4W Q4W Q4W Q3W Overall
(n = 4) (n = 3) (n = 3) (n = 7) (n = 12) (n = 29)
Infusion-related reaction 0 0 0 3 (42.9) 0 3 (10.3)
Back pain 0 0 0 2 (28.6) 0 2 (6.9)
Asthenia 0 0 0 1 (14.3) 1 (8.3) 2 (6.9)
Leukocytosis 0 0 0 0 1 (8.3) 1 (3.4)
Neutrophilia 0 0 0 0 1 (8.3) 1 (3.4)
Cellulitisa 0 0 0 1 (14.3) 0 1 (3.4)
Lymphangitis 0 0 0 1 (14.3) 0 1 (3.4)
Polyuria 0 0 0 1 (14.3) 0 1 (3.4)
Nausea/vomiting 0 0 0 0 1 (8.3) 1 (3.4)
Facial erythema 0 0 0 0 1 (8.3) 1 (3.4)
Dry mouth 0 0 0 0 1 (8.3) 1 (3.4)
Pyrexia 0 0 0 0 1 (8.3) 1 (3.4)
Dysphagia 0 0 0 0 1 (8.3) 1 (3.4)
aDue to drug extravasation
ITT intent-to-treat; Q3W every 3 weeks; Q4W every 4 weeks
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These phase II data demonstrate that administration of
patisiran to patients with FAP led to robust, dose-
dependent, and statistically significant knockdown of
serum TTR protein levels. Mean sustained reduction in
TTR of >80 % was achieved with 2 consecutive doses of
patisiran 0.3 mg/kg dosed every 3–4 weeks, with a max-
imum knockdown of 96 % achieved in the Q3W group.
These knockdown rates are consistent with the rates ob-
served in the single ascending dose, placebo-controlled
phase I study of patisiran [20]. Evidence from other sys-
temic amyloidotic diseases indicates that as little as 50 %
reduction of the disease-causing protein can result in
clinical disease improvement or stabilization [26, 27],
illustrating the potential of this therapy. The degree of
TTR knockdown with patisiran was not affected by pa-
tients taking tafamidis or diflunisal, suggesting that these
TTR stabilizer drugs do not interfere with the pharma-
cologic activity of patisiran. In patients with the Val30-
Met mutation, patisiran suppressed production of both
mutated and wild-type TTR; the latter remains amyloi-
dogenic in patients with late-onset FAP after liver trans-
plantation [28, 29].
Multiple doses of patisiran were shown to be generally
safe and well tolerated in this study. The majority of AEs
were mild or moderate in severity and no dose-limiting
toxicities were observed. While IRRs were the most
common drug-related TEAE seen at 0.3 mg/kg, no IRRs
were reported in the 0.3 mg/kg group that received the
micro-dosing infusion regimen over 70 min. Premedica-
tion was used to reduce the risk of IRRs, and is thusconsidered in assessment of the tolerability of this regi-
men. Glucocorticoids such as dexamethasone can in-
crease white blood cell levels [30], as observed
transiently in this study, and TEAEs potentially related
to premedication will be monitored during longer term
patisiran administration. The generally favorable toler-
ability profile observed in this study, with most patients
receiving TTR stabilizers, is encouraging with respect to
the potential concurrent use of these agents with
patisiran.
This multi-dose study defined patisiran 0.3 mg/kg
Q3W delivered using the 70-min micro-dosing regimen
as the formulation and dosage to administer in the on-
going open-label extension (OLE) phase of patients with
FAP. Whilst both Q3W and Q4W achieved potent TTR
knockdown, the level of TTR suppression was better
maintained between doses with the Q3W schedule,
supporting its future investigation. Preliminary data
from the OLE study show sustained TTR knockdown
of ~80 % after 168 days (9 doses), with no reported
SAEs (n = 27) [31]. The OLE study preliminary safety
data are consistent with the tolerability of patisiran ob-
served in this trial, with TEAEs all mild or moderate in
severity [31].
Patient baseline demographics and disease characteris-
tics in the present study were similar to those reported for
other recent FAP studies. In particular, the mean age
(55.6 years) was comparable to that reported for a large
natural history study of patients with FAP (56.4 years;
n = 283) [32] and for a phase II/III diflunisal study
(59.7 years; n = 130) [15], but was greater than the 39.8/
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the tafamidis phase II/III study (n = 125) [14]. Some
75.9 % of patients in the present study had the Val30Met
mutation compared with 58.5 % (161/275 evaluable pa-
tients), 54.6 %, and 100 % in the natural history, diflunisal,
and tafamidis studies, respectively [14, 15, 32].
The results of this study supported the initiation of
a phase III study of patisiran. APOLLO is a random-
ized, placebo-controlled, phase III study of patisiran
0.3 mg/kg Q3W administered using the 70-min micro-
dosing schedule in recruiting patients with Val30Met
or non-Val30Met FAP who are not taking TTR stabilizers.
The primary study endpoint is disease progression, mea-
sured as the change from baseline in mNIS + 7 score at
18 months (Clinical trial identifier NCT01960348). Sec-
ondary endpoints include measures of quality of life and
disease burden, changes from baseline in motor and auto-
nomic neuropathy measures, and safety.Conclusion
In conclusion, the results of this phase II study provide
evidence that the investigational agent patisiran was gen-
erally well tolerated and effective in reducing both
mutant and wild-type TTR levels in patients with FAP.
The 0.3 mg/kg Q3W dosing schedule is under investiga-
tion in the phase III APOLLO trial.Additional files
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